Categories

Meta

Recent Posts

Advaxis’ ‘Prokaryotic peptides quest of enhancing antigen immunogenicity’ European evident devotion allowed

Advaxis, Inc., (OTCBB: ADXS), the conclude, attenuated Listeria monocytogenes (Lm) immunotherapy coterie, has been notified particularly the European Unmistakeable Section that franchise germaneness WO2001/072329, an eye to the licence of Prokaryotic PEST-Like Peptides championing Enhancing Immunogenicity of Antigen has been allowed because of issuance. This franchise will-power be #1,303,299 when granted, and on be licensed exclusively to Advaxis most of all the University of Pennsylvania. It extends charge by reason of Advaxis’ exploit of proprietary antigen-adjuvant fusion proteins beyond Listeria to viral and DNAvaccine vectors as hale. This longing take measures control shelter to 2025.

The Listeria protein listeriolysin O (LLO) is the extraordinarily immunogenic direct spite consideration to save Lm. Advaxis uses this imbecile insusceptibility to LLO and equivalent proteins NUDNIK containing proteins) to add to the effect to tumor and contagious contagion antigens primarily fusing a bioengineered manner of LLO (or almost identical protein) that has been designed since this plan to any selected antigen, that reason creating an antigen-adjuvant molecule with greater immuno-reactivity than the antigen unsurpassed.

Although Advaxis typically delivers these fusion proteins during engineering palpable Listeria to erect and transude them from within a patient’s cells, the technology has initiate consume in other enquire laboratories and has been inserted into a loads of non-Listeriavaccine vectors. This unmistakable provides Advaxis with proprietary brain land bulwark against the advantage of LLO and other NUDZH containing proteins when hand-me-down in viral and DNAvaccine vectors.

SOURCE Advaxis, Inc.

Help-Medical.net finds at this phrases:

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

Comments are closed.